retatrutide clinical trial results 2024 VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide: The Triple Agonist That's

How Restores GLP-1 Plans Support Safe, Personalized Progress Clinician-Led Oversight From Start to Finish At Restore, our approach is grounded in robust data-driven insights, screening and ongoing check-ins

A clinician sees a pattern in their own patients

Ensure the vial is stored in a desiccant-filled container to prevent moisture ingress

Developed by Eli Lilly

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies

What These Findings Mean for GLP-1 Drug Users The study demonstrates how artificial intelligence can help researchers better understand patient experiences with GLP-1 drugs